Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 5Gynecologic 5Thoracic 4Gastrointestinal 3CNS 3Tumor-Agnostic 2Sarcoma 2Head & Neck 2Breast 2Other hematologic neoplasm 1Myeloid 1

Conditions

Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × adavosertib × Breast × Clear all
NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

AstraZeneca

Phase 2 Active not recruiting
273 enrolled 22 charts
Breast

Triple Negative Breast Neoplasms

NCT03012477 2021-11-23

CISPLATIN + AZD-1775 In Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled 9 charts
Breast

Triple-negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡